Climb Bio (NASDAQ:CLYM) Coverage Initiated by Analysts at Leerink Partners

Equities research analysts at Leerink Partners started coverage on shares of Climb Bio (NASDAQ:CLYM) in a research note issued on Monday,Briefing.com Automated Import reports. The brokerage set an “outperform” rating and a $10.00 price target on the stock. Leerink Partners’ target price indicates a potential upside of 205.81% from the stock’s previous close.

Climb Bio Trading Up 1.2 %

NASDAQ:CLYM traded up $0.04 during trading hours on Monday, hitting $3.27. 896 shares of the company were exchanged, compared to its average volume of 455,574. Climb Bio has a 52-week low of $2.35 and a 52-week high of $11.55. The company has a market cap of $219.82 million, a PE ratio of -1.54 and a beta of -0.34.

About Climb Bio

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.